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Abstract
Background: The association of TGF b1 polymorphisms and atrial fibrillation (AF) in essential hypertensive (EH)
subjects remains unknown. Methods EH subjects with AF (EH+AF+) and sinus rhythm (EH+AF-) were enrolled. The
polymorphisms of +869 T ® C at codon 10 and + 915 G ® C at codon 25, were genotyped. The clinical
characteristics including serum TGF b1 levels were detected.
Results: The GG genotypes of TGF b1 +915 G ® C at codon 25 were more prevalent in subjects from EH+AF+
group than those from EH+AF- group (P = 0.009). The subjects with GG genotype from EH+AF+ group had the
highest mean serum TGF b1 level, which was significantly higher than that of GG genotype subjects from EH+AF-
group (3.18 ± 0.24 ng/dl vs.2.29 ± 0.14 ng/dl, P < 0.05). Multiple analyses revealed that the TGF b1 GG genotype of
+915 G ® C at codon 25 presented a 3.09 times higher risk in developing AF in the multivariate model after
adjusting for age and gender.
Conclusion: The polymorphisms of TGF b1 +915 G ® C at codon 25 were associated with occurrence of AF and
serum TGF b1 level in EH subjects.
Background
Atrial fibrillation (AF) is a common and clinically
important arrhythmia in practice, which represents a
major public health problem. AF induces hemodynamic
impairment and thromboembolic events, resulting in
significant morbidity, mortality, and cost [1,2].
A number of factors, e.g. age, coronary artery disease,
myocardial infarction, heart failure, valvular heart dis-
ease, contribute to the occurrence and development of
AF [3,4]. In addition, population based studies revealed
that hypertension is an independent risk factor for onset
of AF [5]. The risk of developing AF in hypertensives
was 1.9 times higher than normtensives in the Framing-
ham Heart Study [6].
The precise mechanism of AF remains largely
unknown. Compelling evidence showed that the atrial
fibrosis is essential for the onset and maintenance of AF
[7]. Atrial fibrosis causes conduction abnormalities
which results in an increase in AF vulnerability.
Increased atrial fibrosis was observed in the biopsy and
autopsy specimens from patients with AF [7-15].
Transforming growth factor b1, (TGF b1) is a cytokine
that modulates the tissue fibrosis. Previous study
showed that over-expression of TGF b1s e l e c t i v e l y
induced atrial interstitial fibrosis, contributing to AF
vulnerability [16,17]. Inhibition of TGF b1 expression by
certain drug decreased the atrial fibrosis and AF vulner-
ability[18]. These studies suggest that TGF b1p l a ya n
essential role in inducing AF.
The expression of TGF b1 is under gene control. Sev-
eral functional polymorphisms in the TGF b1 gene had
been determined previously. Some of these functional
polymorphisms, e.g. (+869 T ® Ca tc o d o n1 0a n d
+915 G ® C at codon 25) are reported to be associated
with cardiovascular disorders, including myocardial
infarction, artery stiffness and LVH in hypertensives
[19-25].
To date, the association between TGF b1g e n ep o l y -
morphism and the occurrence of AF in hypertensive
subjects remains unknown. We hypothesized that the
TGF b1 polymorphisms genetically determined the
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any medium, provided the original work is properly cited.predisposition to AF in hypertensives. In current study,
we recruited newly diagnosed essential hypertensives
with and without AF to testify this hypothesis.
Methods
Subject Enrollment
Newly diagnosed essential hypertensive subjects were
enrolled in this study. The subjects with documented
AF were assigned into the EH+AF+ group and those
with sinus rhythm were assigned into the EH+AF-
group. To avoid any possible influence of certain anti-
hypertensive drugs on the onset of AF, all subjects
received no treatment when they were enrolled. Hyper-
tension was defined as systolic blood pressure (SBP)> =
140 mm Hg, or diastolic blood pressure (DBP)> =
90 mm Hg in supine position, after 20 min of rest on 2
separate days. AF was determined by 12-lead electrocar-
diography (ECG) and/or 24-h Holter monitoring. Prior
or current documented permanent or paroxysmal AF
was considered as AF subjects. Clinical characteristics
such as age, sex, body mass index (BMI), and smoking
status were collected. Patients with secondary hyperten-
sion, coronary heart disease, diabetes myocardial infarc-
tion and/or other significant heart problems, such as
severe valvular heart disease, dilated phase HCM, conge-
nital heart disease, having other types of arrhythmia, was
excluded. Informed consent was obtained from each
subject and the Institutional Ethninc Board of the uni-
versity approved the study.
Plasma measurements
Blood was collected at morning from resting and fasting
subjects. Lipid profiles (total cholesterol, TC and trigly-
cerides, TG) were determined by enzymatic-colorimetric
methods according to manufacturer instructions on a
Beckman spectrophotometer (Beckman, USA). LDL-C
was calculated by the Friedewald’sf o r m u l a .T h es e r u m
C reaction protein (CRP) concentration was measured
by high sensitivity enzyme immunoassay (Dade-Behring,
Marburg Germany) for the quantitative determination.
Serum TGF b1 detection
The serum TGF b1 was measured using the BDA19
capture ELISA as described previously[26]. The intra-
assay coefficient of variation of the assay used is 6.8%
and the sensitivity (defined as 2 SD above the mean of
16 blank determinations) was ~0.1 ng/ml.
Genotyping
DNA was isolated from the whole blood according to
standard procedures. Genotyping of the TGF-1 poly-
morphisms of the +869 T ® C at codon 10 and +915 G
® C at codon 25 was performed. Briefly, 20 μL of geno-
mic DNA solution was added to D-mix, which contains
the dNTPs and reaction buffer, for the cytokine geno-
typing. Taq polymerase (1.1 μL; Gibco BRL, USA) was
then added to the D-mix, vortexed for 15 seconds, and
10 μL of the D-mix mixture transferred to a 96-well
microtiter genotyping tray with dried primers in each
reaction well. A Perkin-Elmer 9600 thermocycler was
used to amplify the promoter regions by PCR. Samples
were subjected to 10 cycles at 96°C for 10 seconds, and
63°C for 60 seconds, followed by 20 cycles at 96°C for
10 seconds, annealing temperature of 59°C for 50 sec-
onds, and 72°C for 30 seconds. After the PCR process,
the amplified DNA fragments were separated by agarose
gel electrophoresis and visualized by staining with ethi-
dium bromide and exposure to ultraviolet light in an
UV transilluminator.
Statistical analysis
A l ld a t aw e r ea n a l y z e db yS P S S( v e r s i o n1 3 . 0 )s o f t w a r e .
The clinical characterstics between EH+AF+ and
EH+AF- were compared by t test. The Serum TGF b1
levels according to the genotype distributions were per-
formed by the ANOVA test and pos hoc analysis. The
genotype distributions and allele frequencies of TGF b1
in two groups were evaluated by c
2-test. Logistic regres-
sion analysis was performed to assess the odd ratio (OR)
for AF in EH subjects. P value ≤ 0.05 was considered
statistically significant.
Results
The clinical and biochemicald a t ao fa l ls u b j e c t sw e r e
listed in Table 1. There were no significant differences
in age, sex, height, weight, BMI, SBP, DBP, serum TG,
TC, HDL-C, and LDL-C between EH+AF- and EH+AF-
groups. The mean serum CRP level was markedly higher
in the EH+AF+ group than in the EH+AF- group.
Table 1 Clinical and biochemical characteristics of
all subjects
AF+ AF- P
Age (years) 45.6 ± 6.7 46.1 ± 4.9 NS
Height (cm) 175.4 ± 8.5 175.2 ± 6.4 NS
Weight (kg) 58.6 ± 9.2 59.1 ± 5.8 NS
Smoker (%) 66.4 47.8 0.02
SBP (mmHg) 155.6 ± 11.4 153.9 ± 9.9 NS
DBP (mmHg) 89.6 ± 6.8 90.6 ± 7.5 NS
BMI 25.6 ± 1.6 25.9 ± 2.1 NS
TG (mg/dl) 122 ± 13.7 124 ± 9.6 NS
TC (mg/dl) 196.6 ± 14.8 200.5 ± 16.3 NS
HDL-C (mg/dl) 49.8 ± 5.8 51.5 ± 8.2 NS
LDL-C (mg/dl) 113.7 ± 10.8 111.6 ± 8.1 NS
CRP (mg/dl) 2.116 ± 0.08 1.081 ± 0.06 <0.001
TGF b1 (ng/ml) 2.23 ± 0.12 2.22 ± 0.16 NS
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EH+AF- group. The mean serum TGF b1 levels did not
show significant difference between two groups.
Table 2. showed the genotype distributions and allele
frequencies of TGF b1 in two groups. All the allele fre-
quencies fit in with the Hardy-Weinberg equilibrium
law. For the polymorphisms of + 915 G ® C at codon
25, the GG genotype was more prevalent in the EH+AF
+ subjects than in the EH+AF- subjects (P = 0.009). For
the polymorphisms of +869 T ® C at codon 10, no sig-
nificant difference were noted between the two groups
(P = 0.075).
Figure 1. showed the serum TGF b1 levels according
t ot h eg e n o t y p ep r o f i l e s .A l t h o u g hT a b l e1 .s h o w e dn o
significant difference Iin the overall mean TGF b1 levels
between EH+AF+ and EH+AF- groups (2.23 ± 0.12
vs.2.22 ± 0.16, NS), we observed that the subjects with
GG genotype from EH+AF+ group had the highest
mean serum TGF b1 level, which was significantly
higher than that of GG genotype subjects from EH+AF-
group (3.18 ± 0.24 vs. 2.29 ± 0.14, ng/dl, P < 0.05).
When it was compared to the GC and CC genotypes
from both EH+AF+ and EH+AF- groups, statistically
differences were noted as well (all P < 0.05). For the
genotypes from the +869 T ® C at codon 10, the mean
TGF b1 levels were similar among subjects with differ-
ent genotypes in both EH+AF+ and EH+AF- groups.
Table 3. showed the odd ratio (OR) for AF in EH sub-
jects. As determined by the logistic regression analysis,
the TGF b1 GG genotype presented a 3.09 times higher
risk in developing AF in the multivariate model after
adjusting for age and gender. As shown in Table 3., the
other risk factors for AF subjects included age, CRP
level and smoke.
Discussion
The present study assessed the association between the
single nucleotide polymorphisms at the TGF b1l o c u s
and AF in subjects with essential hypertension. We
found that the GG genotype of TGF b1 +915 G->C at
codon 25 was more prevalent in the individuals with AF
than those without. Multiple analyses revealed that the
GG genotype carriers presented an odd ratio of 3.09 for
developing AF. The +869 T->C at codon 10 showed no
positive relation with AF. As far as we know, this is the
first study regarding the association between the TGF
b1 polymorphisms and AF in hypertensives.
TGF b1 is a cytokine that regulates the synthesis of
extracellular matrix components such as collagen, fibro-
nectin, and proteoglycan. The role of TGF b1 in cardiac
fibrosis and AF had been studied. Over-expression of
Table 2 Distributions of genotype distribution and allele
frequenies of TGF b1
EH+Af+ (n = 240) EH+Af- (n = 300) X
2 P
Condon 25 G/C
GG 106 94 9.54 0.009
GC 74 110
CC 60 96
Condon 10 T/C
TT 87 108 0.52 0.975
TC 79 97
CC 74 95
Figure 1 Serum TGFb1 level according to the genotype profile.
Table 3 OR to AF determined by logistic regressiona
analysis
Variable Odd Ratio (95% CI) P
TGF b1 GG genotype 3.09 (2.11-6.59) <0.01
Age (years) 1.45 (1.11-2.32) 0.04
CRP (mg/dl) 1.81 (1.15-3.49) 0.03
Smoker (%) 2.47 (1.98-4.66) 0.01
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increased conduction heterogeneity and AF vulnerability
without affecting the cellular electrophysiology[16]. Inhi-
bition of TGF b1 expression by pirfenidone (PFD) sig-
nificantly reduced the atrial fibrosis, as a result, reduced
conduction abnormalities and AF vulnerability were
observed[18]. These studies suggest that the TGF b1
attribute to development of AF via triggering atrial
fibrosis. Higher levels of serum or plasma TGF b1h a v e
been observed in subjects with hypertension, in associa-
tion with cardiac and renal complications [27-31]. The
TGF b1 condon 25 polymorphisms are located in the
signal peptide sequence, which regulate the export of
synthesized TGF b1 protein across membranes of the
endoplasmic reticulum and the activation of protein.
Previous studies showed that the TGF b1 levels of sub-
jects with GG genotype were markedly higher than
those with GC and CC genotypes in heart and lung
transplant patients[32,33]. In consistent with these stu-
dies, we found that the subjects with codon 25 G/G
genotype had higher TGF b1 plasma level in subjects
from EH+AF+groups than those with the same genotype
from EH+AF- groups, although no significant difference
of overall mean TGF b1 levels between EH+AF+ and
EH+AF- groups was observed.
In the ECTIM Study, Rao et al. reported the G/C gen-
otype at codon 25 provided a 2.3-fold greater risk for
the presence of vascular disease in hemodialysis patients
[22]. Xu and his colleagues reported genetic role of TGF
b1 Arg25Pro polymorphisms (GC genotype in present
study) in the occurrence of left ventricle hypertrophy in
EH subjects [25]. Our data showed that the GG geno-
type, rather than GC genotype, was related to AF inci-
dence in EH subjects. This inconsistency may be
explained in part by the difference in study protocol and
relatively small scale samples in these studies.
All EH subjects in our study were newly diagnosed
and none of them received anti-hypertensive treatment
at enrollment. This is important because some antihy-
pertensive agents, e.g. b blockers and angiotension con-
verting enzyme inhibitors and Angiotensin II receptor
blockers may inhibit the onset and maintenance of AF.
Taken together, in present study we found the GG
genotype of TGF b1 +915 G->C at codon 25 was asso-
ciated with occurrence of AF in EH subjects. This find-
ing may help to evaluate the risk of developing AF in
EH patients for a reinforced prevention.
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